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Abstract  
Glutamate transporter-1 (GLT-1) is the main glutamate transporter in the brain. 
Dysfunctional GLT-1 has been suggested to cause glutamate uptake impairments in 
Huntington disease (HD). It is thought that simply increasing GLT-1 expression can 
increase glutamate uptake in the brain. However, the functional effect of increasing GLT-
1 expression in HD or the healthy brain has not been studied. We increased GLT-1 
expression using two compounds, ceftriaxone and LDN/OSU-0212320 (LDN), and used 
the iGluSnFR technique to visualize glutamate dynamics in real-time. We found an 
impairment in glutamate uptake in the HD hippocampus in mice that was surprisingly not 
alleviated by ceftriaxone treatment. Furthermore, we found that increasing GLT-1 
expression through ceftriaxone or LDN treatment in the healthy brain had no effect on 
glutamate uptake. These results suggest that increasing glutamate uptake is much more 
complex than just increasing GLT-1 expression.  
  
iii 
 
ACKNOWLEDGMENTS  
First and foremost, I would like to thank my supervisor Dr. Matthew Parsons for his 
never-ending support and guidance. He took a chance on me as a graduate student when 
no one else would even speak to me; for that I am ever grateful.  
I would like to thank our research assistant, Firoozeh Nafar, for her positivity, support, 
and her help in teaching me how to perform western blots.  
I also have the utmost appreciation for my lab mates. Thank you for performing 
dissections for me when I was hesitant about sacrificing mice and for making the lab fun 
every single day.  
Finally, I would like to thank the other graduate students for their guidance and help with 
imposter syndrome, as well as my family for always providing me with love and support.  
  
iv 
 
Chapter 1 Table of Contents 
Chapter 1 Introduction ......................................................................................................... 1 
1.1 An Introduction to Glutamate Neurotransmission ................................................ 1 
1.1.1 Glutamate transporters ................................................................................... 5 
1.1.2 GLT-1 and Glutamate Clearance ................................................................... 8 
1.2 Methods to research glutamate dynamics ........................................................... 10 
1.2.1 Microdialysis ................................................................................................ 10 
1.2.2 Synaptically-Activated Transporter Currents .............................................. 10 
1.2.3 Biochemical Uptake Assay .......................................................................... 11 
1.2.4 Fluorescent Biosensor of Glutamate ............................................................ 11 
1.3 An Introduction to Huntington Disease .............................................................. 12 
1.3.1 Symptoms and Treatment ............................................................................ 13 
1.3.2 Mouse models of HD ................................................................................... 14 
1.3.3 Glutamate uptake and GLT-1 in HD ........................................................... 17 
1.3.4 Long-Term Potentiation (LTP) and HD....................................................... 20 
1.4 Pharmacological ways to increase GLT-1 expression ........................................ 22 
1.5 Aims and Hypothesis .......................................................................................... 23 
Chapter 2: Materials and Methods ..................................................................................... 24 
2.1 Animals and Drugs .............................................................................................. 24 
v 
 
2.2 Stereotaxic Surgery ............................................................................................. 25 
2.3 Slice Preparation ................................................................................................. 26 
2.4 Imaging and image analysis ................................................................................ 27 
2.5 Electrophysiology for experiment 1 (HFS LTP) ................................................. 28 
2.6 Western Blots ...................................................................................................... 29 
2.7 Statistics .............................................................................................................. 30 
Chapter 3 Results ............................................................................................................... 31 
3.1 Experiment 1: Treating an animal model of HD with ceftriaxone ...................... 31 
3.1.1 Characterization of extracellular glutamate dynamics in the hippocampus 
during HFS ................................................................................................................. 31 
3.1.2 Characterization of glutamate dynamics in the hippocampus during TBS .. 35 
3.1.3 GLT-1 expression in hippocampal tissue from WT and Q175FDN mice ... 38 
3.1.4 HFS LTP experiments .................................................................................. 41 
3.2 Experiment 2: Pharmacologically increasing GLT-1 expression in the healthy 
brain.…………………………………………………………………..……………….41 
3.2.1 Glutamate Clearance in the Cortex after GLT-1 Upregulation.................... 42 
3.2.2 Glutamate Clearance in the Hippocampus after GLT-1 Upregulation ........ 49 
3.2.3 Glutamate Clearance in the Striatum after GLT-1 Upregulation ................. 55 
Chapter 4 Discussion ......................................................................................................... 61 
vi 
 
4.1 Using ceftriaxone to treat the Q175FDN mouse model of HD ........................... 61 
4.1.1 Glutamate Dynamics in the Hippocampus during HFS and TBS 
stimulation...................................................................................................................61 
4.1.2 Ceftriaxone does not Alleviate LTP Impairments in HD and Impairs LTP in 
WT Mice ..................................................................................................................... 63 
4.1.3 Ceftriaxone did not increase GLT-1 expression in aged animals ................ 64 
4.2 Pharmacologically increasing GLT-1 expression in the brain ............................ 65 
4.2.1 Ceftriaxone Treatment to Increase GLT-1 Expression ................................ 66 
4.2.2 LDN Treatment to Increase GLT-1 Expression ........................................... 69 
4.3 Conclusion ........................................................................................................... 70 
REFERENCES .................................................................................................................. 71 
APPENDIX ........................................................................................................................ 94 
 
 
  
vii 
 
List of Tables 
 
Table 1.1 Summary of HD mouse models ..................................................................................... 18 
 
 
 
  
viii 
 
List of Figures 
Figure 1.1 Schematic of a Tripartite Synapse.. .................................................................... 2 
Figure 1.2 Glutamate Clearance Impairments can Cause a Spillover Effect ....................... 6 
Figure 3.1 Characterization of glutamate dynamics in the hippocampus during HFS ...... 33 
Figure 3.2 Characterization of glutamate dynamics in the hippocampus during TBS ...... 36 
Figure 3.3 GLT-1 expression. ............................................................................................ 39 
Figure 3.4 Characterization of glutamate dynamics in the cortex after ceftriaxone 
treatment. ........................................................................................................................... 44 
Figure 3.5 Characterization of glutamate dynamics in the cortex after LDN 
treatment………………………………………………………………………………….47 
Figure 3.6 Characterization of glutamate dynamics in the hippocampus after ceftriaxone 
treatment. ........................................................................................................................... 50 
Figure 3.7 Characterization of glutamate dynamics in the hippocampus after LDN 
treatment. ........................................................................................................................... 53 
Figure 3.8 Characterization of glutamate dynamics in the striatum after ceftriaxone 
treatment ............................................................................................................................ 56 
Figure 3.9 Characterization of glutamate dynamics in the striatum after LDN treatment. 59 
 
 
 
 
ix 
 
List of Abbreviations 
℃: Degrees Celsius   
%: Percent  
µA: Microampere  
µl: Microlitre  
µM: Micromolar  
3-NPA: 3-Nitropropionic acid 
AD: Alzheimer disease 
ACSF: Artificial cerebral spinal fluid 
ALS: Amyotrophic lateral sclerosis 
AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
APS: Ammonium persulfate 
BSA: Bovine serum albumin  
BME:  Beta- mercaptoethanol   
Ca2+: Calcium  
CAG: Cytosine-Adenine-Guanine 
x 
 
CaMKII: Calmodulin-dependent protein kinase II  
Cef: Ceftriaxone 
Cl-: Chlorine  
CNS: Central nervous system 
DMSO: Dimethylsulfoxide  
DTBZ: Deutetrabenazine  
EAAT1: Excitatory amino acid transporter 1  
EAAT2: Excitatory amino acid transporter 2  
EAAT3: Excitatory amino acid transporter 3   
EAAT4: Excitatory amino acid transporter 4  
EAAT5: Excitatory amino acid transporter 5  
EPSCs: Excitatory postsynaptic currents  
ERK: Extracellular-signal regulated kinase 
ex-NMDARs: Extrasynaptic NMDARs 
F/F: Fluorescence/ fluorescence   
FDA: Food and Drug Administration  
fEPSP: field excitatory post-synaptic potential 
GABA: Gamma-aminobutyric acid  
xi 
 
GFAP: Glial fibrillary acidic protein   
GFP: Green fluorescent protein  
GLAST: Glutamate aspartate transporter   
GLT-1: Glutamate transporter-1  
H&E: Haemotoxylin & Eosin  
HD: Huntington disease 
HET: Heterozygous  
HFS: High frequency stimulation   
HOM: Homozygous  
HTT: Huntingtin gene 
Htt: Huntingtin protein  
Hz: Hertz  
IB: Inclusion bodies 
iGluSnFR: Intensity-based glutamate sensing fluorescent reporter  
i.p.: Intraperitoneal  
IOS: Intrinsic Optical Signal 
IT15: Interesting transcript 15 
K+: Potassium 
xii 
 
Kt: Transport affinity 
LED: Light-emitting diode  
LTP: Long term potentiation  
Mg2+: Magnesium  
mGluR: Metabotropic glutamate receptor 
mHtt: Mutant huntingtin 
mM: Millimolar 
mRNA: Messenger RNA 
ms: Millisecond 
Na+: Sodium  
NF-κB: Nuclear factor-kappaB 
nM: Nanomolar 
NMDA – N-methyl-D-aspartate 
NMDAR: N-methyl-D-aspartate receptor 
PKA: Protein kinase A 
PKC: Protein kinase C 
ROI: Region of interest  
RM ANOVA: Repeated measure ANOVA 
xiii 
 
RT-PCR: Reverse transcription-polymerase chain reaction  
s.c.: Subcutaneous  
Sal: Saline 
siRNA: Small interfering RNA 
STC: Synaptically-activated transporter current 
syn-NMDARs: Synaptic NMDARs 
TBS: Theta burst stimulation 
TBS-T: Tris-buffered saline-Tween20 
TBZ: Tetrabenazine  
VMAT: Vesicular monoamine transporters  
WT: Wild-type 
YAC: Yeast artificial chromosome  
Yb-1: y-box-binding protein 1  
  
xiv 
 
CO-AUTHORSHIP STATEMENT  
 
 
I, Crystal Wilkie, am first author of this manuscript. I performed all of the experiments 
except for the HFS LTP experiments which are shown in the Appendix (Figure A1). 
These HFS-LTP data were completed by our honours student Cherry-Lynn Benson and 
were obtained from animals that I had treated with saline or ceftriaxone.  
 
 
1 
 
Chapter 1 Introduction 
1.1 An Introduction to Glutamate Neurotransmission 
Glutamate, an amino acid, is the brain’s most abundant excitatory neurotransmitter. 
Glutamatergic synapses are typically tripartite synapses containing a presynaptic neuron, 
postsynaptic neuron, and a surrounding glial cell (Figure 1.1). During typical glutamate 
neurotransmission, synaptic vesicles containing glutamate fuse with the presynaptic 
membrane and glutamate is released into the extracellular space via exocytosis (Naito & 
Ueda, 1983; Cousin & Robinson, 1999). Once in the synaptic cleft, glutamate can bind to 
glutamate receptors which can be ionotropic or metabotropic and located on either the 
pre- and/or post-synaptic membranes (Reiner & Levitz, 2018). Ionotropic glutamate 
receptors include α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), 
kainate, and N-methyl-D-aspartate (NMDA) receptors. Metabotropic receptors are 
subdivided into three groups: group 1 (mGluR1, mGluR5) are mainly located post-
synaptically and responsible for enhancing neuronal excitability; group II (mGluR2 and 
mGluR3) are located on presynaptic and postsynaptic membranes and are involved in 
inhibiting neurotransmitter release; and group III (mGluR4, mGluR6, mGluR7, and 
mGluR8) serve the same function as group II except they are predominately located on 
postsynaptic membranes in the cerebellum (Niswender & Conn, 2010).  
AMPA receptors (AMPARs) are tetramers that consist of various combinations of 
four distinct subunits; GluA1-GluA4 (Song & Huganir, 2002). These receptors are 
typically permeable to Na+, K+, and can be permeable to Ca2+; however, Ca2+ ion influx is 
prevented by the presence of a GluA2 subunit (Man, 2011). AMPARs exhibit rapid 
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Figure 1.1 Schematic of a Tripartite Synapse. There are three main aspects to a tripartite 
synapse; a presynaptic neuron which releases glutamate, a postsynaptic neuron where the 
glutamate receptors are located, and a surrounding glial cell responsible for removing 
excess neurotransmitter. Image created using Biorender.  
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presence of a GluA2 subunit (Man, 2011). AMPARs also exhibit rapid activation and 
inactivation kinetics, with AMPAR-mediated excitatory postsynaptic currents (EPSCs) 
decaying within milliseconds (Colquhoun et al., 1992; Hestrin, 1992; Clements et al., 
1998).  
Compared to AMPARs, NMDARs have slow activation and inactivation kinetics, 
high permeability to Ca2+, and a Mg2+ blockage at resting membrane potential (Dzubay & 
Jahr, 1996). To activate NMDARs three events must occur: glutamate binding, removal 
of Mg2+ blockade by postsynaptic depolarization, and binding of either glycine or D-
serine which are co-agonists (Dore et al., 2017; Traynelis et al., 2010). Due to their slow 
inactivation kinetics and high affinity for glutamate (Traynelis et al., 2010), these 
receptors show a longer duration EPSC than AMPARs (Lester & Jahr, 1992). 
Structurally, these receptors are heterotetramers that consist of two obligatory GluN1 
subunits plus any combination of GluN2A-D and/or GluN3A-B subunits (Traynelis et al., 
2010). NMDARs can be located synaptically (syn-NMDARs) as well as extrasynaptically 
(ex-NMDARs) on the postsynaptic neuron, and can also exist presynaptically 
(Hardingham & Bading, 2010; Banerjee et al., 2015).  
While glutamate is necessary for fast excitatory neurotransmission and for many 
forms of activity-dependent synaptic plasticity (Danbolt, 2001; Fonnum, 1984; Ottersen 
& Storm-Mathisen, 1984), glutamate can accumulate in the extracellular space to toxic 
levels if not properly regulated. An accumulation of glutamate leads to a spillover effect 
which can activate ex-NMDARs and is thought to cause synaptic plasticity impairments 
(Li et al., 2011) and cell death (Hardingham & Bading, 2010; Parsons and Raymond, 
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2014) as shown in Figure 1.2. Efficient transporter-mediated glutamate uptake is required 
to prevent this excitotoxicity (Danbolt, 2001; Parsons & Raymond, 2014).   
1.1.1 Glutamate transporters 
Glutamate transporters are sodium-dependent transporters that are located on both 
neurons and astrocytes (Rothstein et al., 1994; Danbolt, 2001). Currently, there are five 
known glutamate transporters. Glutamate transporter-1 (GLT-1, also known as excitatory 
amino acid transporter 2 or EAAT2) is the brain’s most abundant transporter and is 
primarily located on astrocytes (Danbolt et al., 1992; Tanaka et al., 1997; Otis & 
Kavanaugh, 2000). It is expressed brain-wide with the highest concentrations observed in 
the hippocampus and neocortex (Danbolt et al., 1992; Levy et al., 1993). Another 
glutamate transporter, called glutamate aspartate transporter (GLAST; also known as 
excitatory amino acid transporter 1 or EAAT1), is also highly expressed on astrocytes 
throughout the brain with a higher concentration of transporter expression levels detected 
in the cerebellum (Rothstein et al.,1995; Schmitt et al., 1997; Berger & Hediger, 1998). 
Excitatory amino acid transporter 3 (EAAT3) is predominately expressed on neuronal 
membranes while excitatory amino acid transporter 4 (EAAT4) is found on neuronal 
membranes in the cerebellum (Rothstein et al. 1994; Shashidharan et al., 1997; Dehnes et 
al., 1998; Holmseth et al., 2012). Excitatory amino acid transporter 5 (EAAT5) has low 
expression levels in the brain and is predominately located on retinal photoreceptors and 
bipolar cells (Fairman et al., 1995). Despite the widespread presence of multiple 
glutamate transporters throughout much of the neuroaxis, GLT-1 is thought to be the most  
  
6 
 
Figure 1.2 Glutamate Clearance Impairments can Cause a Spillover Effect. If glutamate 
transporters, in particular GLT-1, are dysfunctional or downregulated then glutamate 
clearance is impaired. This causes an accumulation of glutamate in the extracellular space 
that spills over and activates ex-NMDARs. Image created using Biorender.  
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important transporter involved in glutamate clearance (Danbolt et al., 1992; Tanaka et al., 
1997; Otis & Kavanaugh, 2000). 
1.1.2 GLT-1 and Glutamate Clearance  
GLT-1 co-transports one molecule of glutamate, three molecules of Na+ and one 
H+ into the cell and counter-transports one molecule of K+ with each cycle (Wadiche et 
al., 1995; Danbolt 2001). GLT-1 is a homomer that is composed of three subunits in a 
bowl shape with the glutamate binding site located at the bottom of the bowl (Yernool et 
al., 2004; Tzingounis & Wadiche, 2007). When glutamate and the co-transported ions are 
not bound to the transporter, the glutamate binding site is exposed to the extracellular 
space. Once these molecules bind, the conformation of the transporters change with the 
glutamate binding site facing the cytoplasm. When the counter-transported K+ molecule 
binds to the inward conformation, the conformation changes again so the glutamate 
binding site is facing the extracellular space (Tzingounis & Wadiche, 2007). 
GLT-1 is primarily located on astrocytes and is thought to be responsible for the 
removal of approximately 90% of glutamate from the extracellular space (Danbolt et al., 
1992; Tanaka et al., 1997; Otis & Kavanaugh, 2000). The concentration of GLT-1 at 
synaptic membranes has been suggested to be regulated by neural activity (Benediktsson 
et al., 2012). When neural activity is blocked there is a reduction of GLT-1 clusters near 
synapses, whereas enhanced neural activity increases the size of GLT-1 clusters and their 
proximity to synapses (Benediktsson et al., 2012). The removal of GLT-1 at synapses, in 
the timescale of minutes, occurs through endocytosis and is thought to be mediated by 
protein kinase C (PKC; Robinson, 2006) and ubiquitination, a post-translational 
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modification, which transfers the protein to recycling endosomes (Martínez-Villarreal et 
al., 2012). GLT-1 can also be translocated from the recycling endosomes back to the 
plasma membrane by deubiquitination of the GLT-1 protein (Martínez-Villarreal et al., 
2012).  
When the gene encoding the GLT-1 protein is knocked out, the resultant elevated 
level of extracellular glutamate causes lethal seizures in mice (Tanaka et al., 1997). In 
diseases such as Alzheimer Disease (AD; Li et al., 1997; Hefendehl et al., 2016), epilepsy 
(Tanaka et al., 1997), and Huntington Disease (HD; Estrada-Sánchez et al., 2009; Huang 
et al., 2010), it is thought that dysfunctional GLT-1 causes an accumulation of 
extracellular glutamate which causes a spillover effect and is excitotoxic. Therefore, 
upregulating GLT-1 expression and/or function is considered to be an important 
therapeutic strategy in diseases characterized by excessive glutamate levels.  
While glutamate transporters, in particular GLT-1, are the focus when researching 
glutamate clearance, there are many factors other than GLT-1 expression that affect 
uptake. Recently, it was shown that different brain regions clear glutamate at different 
efficiencies in response to synaptic activity. The hippocampus was more efficient than 
both the cortex and striatum at clearing glutamate especially during higher levels of 
activity where the transporters of the hippocampus seemed less overwhelmed than the 
other two regions (Pinky et al., 2018). This difference in clearing glutamate based on 
brain region may be explained by synapse morphology. Chai et al. (2017) used serial 
electron microscopy to show that astrocytes in the striatum are further away from the 
post-synaptic density than in the hippocampus. Furthermore, the tortuosity of the 
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extracellular space can affect clearance by hindering the free diffusion of molecules 
(Hrabětová, 2005). Finally, if surface mobility of GLT-1 is blocked then glutamate 
clearance has been shown to be impaired (Murphy-Royal et al., 2015). Therefore, there 
are many factors that contribute to glutamate clearance efficiency other than overall GLT-
1 expression levels.  
1.2 Methods to research glutamate dynamics 
1.2.1 Microdialysis 
Microdialysis is based on the principal of diffusion and the microdialysis probe 
typically consists of a semipermeable dialysis membrane (Chefer et al., 2009). To 
measure extracellular levels of a specific neurotransmitter, the no-net-flux method can be 
used. Artificial cerebral spinal fluid (ACSF) containing several different concentrations of 
neurotransmitter is perfused into the probe. Next, the amount of neurotransmitter gained 
to or lost from the probe is measured (Lonnroth et al., 1987; Justice, 1993; Miller et al., 
2008). While this method can estimate the ambient concentration of a specific 
neurotransmitter, microdialysis suffers from poor spatial and temporal resolution.  
1.2.2 Synaptically-Activated Transporter Currents 
When glutamate is transported across the membrane it causes an influx of positive 
charge into the cell (Brew & Attwell, 1987), resulting in synaptically-activated 
transporter currents (STCs) that can be measured by whole-cell patch clamp recordings. 
Typically, this method is performed on astrocytes and has been used in multiple brain 
regions including the cortex (Armbruster et al., 2014; Armbruster et al., 2016), 
hippocampus (Bergles & Jahr, 1997; Diamond & Jahr, 2000), and striatum (Parsons et al., 
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2016). However, this technique is time consuming, technically demanding, and is difficult 
to elicit in brain regions with weak glutamatergic afferents.   
1.2.3 Biochemical Uptake Assay 
The biochemical uptake assay has been used in neuronal and/or astrocyte cultures 
or synaptosome preparations (pinched-off nerve endings) to measure exogenous 
glutamate uptake in various brain regions (Rothstein et al., 1992; Höltje et al., 2008; 
Huang et al., 2010, Parsons et al., 2016). The biochemical uptake assay involves 
homogenizing the culture or synaptosomes, incubating the homogenate in exogenous 
radio-labeled glutamate for several minutes, and measuring the amount of exogenous 
glutamate incorporated into the homogenate to determine uptake efficiency. While the 
biochemical uptake assay is perhaps the most commonly used method to measure 
glutamate uptake, it suffers from poor spatial and temporal resolution. Synaptic 
morphology is non-existent in this assay and the quantification of uptake relies on the 
bulk application of exogenous glutamate for several minutes; however, glutamatergic 
neurotransmission occurs over milliseconds. Finally, it has been suggested that 
biochemical uptake assays overemphasize the contribution of neuronal uptake in total 
glutamate transport, thereby questioning their physiological relevance (Petr et al., 2015).  
1.2.4 Fluorescent Biosensor of Glutamate 
Intensity-based glutamate sensing fluorescent reporter (iGluSnFR) is an extracellular 
sensor of glutamate which allows the visualization of glutamate dynamics in real-time 
(Marvin et al., 2013). iGluSnFR was designed as a circular green fluorescent protein 
(GFP) molecule fused to an extracellular glutamate binding site. At rest, the GFP 
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fluoresces at a low-intensity and when glutamate binds to iGluSnFR there is a 
conformational change that increases GFP fluorescence intensity. As well, iGluSnFR can 
be injected directly into the brain using an adeno-associated virus which infects the cells 
of the injected brain region with iGluSnFR. It can be expressed under the glial fibrillary 
acidic protein (GFAP) or synapsin promoter to be selectively expressed in astrocytes or 
neurons, respectively. When the biochemical uptake assay and iGluSnFR were compared 
by measuring glutamate clearance in the striatum of both the R6/2 and YAC128 mouse 
models of Huntington’s Disease (HD), it was found that the biochemical uptake assay 
showed a significant deficit in glutamate clearance; however, iGluSnFR results suggested 
that there was no deficit in glutamate clearance (Parsons et al., 2016). Therefore, it is 
important to use a method that keeps synapse morphology intact and allows the 
visualization of endogenous glutamate clearance. The present thesis uses iGluSnFR to 
further explore glutamate dynamics in the HD brain.   
1.3 An Introduction to Huntington Disease  
HD is a progressive neurodegenerative disease characterized by a triad of motor, 
cognitive, and psychiatric symptoms. This disease is caused by a trinucleotide cytosine-
adenine-guanine (CAG) repeat expansion (MacDonald et al., 1993) located on the 
Huntingtin (HTT) gene on chromosome four (Gusella et al., 1983). A normal HTT gene 
typically contains between 10 and 35 CAG repeats which encodes the polyglutamine tract 
of the resultant huntingtin protein. Individuals with CAG repeats that exceed 35 are at 
risk of developing HD (Myers et al., 1998); those expressing 36-39 repeats have 
incomplete penetrance and may or may not develop HD during their lifetime, whereas 
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individuals with 40 and above repeats show complete penetrance and will develop HD in 
their lifetime (Brocklebank et al., 2009). Further research showed that the length of CAG 
repeats is negatively correlated with age of onset (Andrew et al., 1993). While the typical 
age of onset is around forty years of age (Hayden, 1981), juvenile HD has an age of onset 
under 20 years old (Andrew et al., 1993).  
1.3.1 Symptoms and Treatment 
HD is characterized by a triad of motor, cognitive, and psychiatric symptoms. 
Motor symptoms in HD are considered to be due to the severe neurodegeneration of the 
striatum, a subcortical brain structure important for motion control. HD patients present 
with jerky involuntary movements known as chorea. Cognitive deficits commonly occur 
in spatial working memory, spatial recognition memory, object recognition memory, and 
episodic memory (Giralt et al., 2012). Psychiatric symptoms usually consist of 
depression, irritability, increased suicidality, anxiety, and apathy (Paulsen et al., 2001). 
Although a formal clinical diagnosis is typically not made until overt motor symptoms 
appear, cognitive and psychiatric symptoms have been shown to appear up to 15 and 20 
years before diagnosis, respectively (Duff et al., 2007; Paulsen et al., 2013). Cognitive 
symptoms are considered by patients and caregivers to be the most debilitating aspect of 
the disease (Duff et al., 2010; Paulsen, 2011; Paulsen et al., 2013).  
Currently, there are only treatments to manage HD symptoms, in particular the 
motor symptoms. Tetrabenazine (TBZ), a vesicular monoamine transporter, was the first 
Food and Drug Administration (FDA) approved treatment for HD (Huntington Study 
Group, 2006). The second FDA-approved treatment for HD was Deutetrabanzine (DTBZ) 
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which is also currently used to help manage the symptoms of chorea (Huntington Study 
Group, 2016). DBTZ is the same as TBZ except it contains deuterium which extends the 
metabolic half-life of the drug to decrease the doses HD patients need to take. The 
efficacy of these drugs is moderate at best, and there are no specific drugs to help treat the 
cognitive symptoms in HD or to slow overall disease progression. Thus, it is important to 
increase our understanding of the neurobiology of HD so that better therapeutic targets 
can be identified. 
1.3.2 Mouse models of HD  
1.3.2.1 Lesion Models  
Lesion models of HD were the first animal models of HD. The excitotoxic animal 
model of HD involved injecting glutamate analogs (such as kainic acid and quinolinic 
acid) into the striatum of rats which produced similar histological, neurochemical, and 
behavioural changes seen in HD (Coyle & Schwarcz, 1976; McGeer & McGeer, 1976). 
The excitotoxic animal model implicated excessive amounts of glutamate as an important 
pathophysiology of HD. However, this model causes the quick development of striatal 
lesions while HD involves slow lesion development over time (Pouladi et al., 2013); 
therefore, it was important to develop mouse models that more closely recapitulate human 
HD for preclinical testing of potential treatments. 
1.3.2.2 N-Terminal Transgenic Models 
Three years after the discovery of the expanded CAG repeat as the cause of HD, 
the first transgenic mouse model was developed. The R6/1 and R6/2 transgenic mice both 
express exon 1 of the human HD gene under the human huntingtin promoter, with around 
15 
 
115 and 150 CAG repeats, respectively (Mangiarini et al., 1996). The R6/2 model 
expresses higher levels of mutant huntingtin and is more aggressive than the R6/1 model. 
Body tremors develop in R6/1 (Harrison et al., 2013) and R6/2 (Lione et al., 1999) mice 
at approximately 7 months and 8 weeks of age, respectively. As well, R6/1 mice exhibit 
cognitive deficits beginning at 12 weeks of age (Nithianantharajah et al., 2008) while the 
R6/2 mice show learning and memory impairments during cognitive tests such as the 
Morris water maze starting as early as 3.5 weeks of age, which is the approximate age of 
puberty in mice (Lione et al., 1999).  Furthermore, R6/1 mice develop a depressive-like 
phenotype at when they have reached mature adulthood, approximately 12 weeks of age 
(Pang et al., 2008) while R6/2 mice develop anxiety, as shown by elevated plus maze, at 
approximately 6 weeks of age (File et al., 1998). A caveat of the R6/1 and R6/2 
transgenic models is that they only express the N-terminal fragment of the huntingtin 
protein.   
1.3.2.3 Full-length Transgenic Models 
The first full-length transgenic HD mouse model was created using yeast artificial 
chromosome (YAC; Hodgson et al., 1999). YACs containing human genomic DNA 
containing the full-length HTT gene were introduced to mice. The first YAC HD clones 
were engineered to contain 46 CAG repeats (YAC46) or 72 CAG repeats (YAC72). The 
YAC72 model developed a HD-like behavioral phenotype at approximately six months 
and developed intranuclear aggregates and neurodegeneration in the striatum. At present, 
the most commonly used YAC model is the YAC128 model. These mice show 
hyperkinesia at three months, a deficit in rotarod performance at six months of age and 
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evident striatal atrophy at nine months of age (Slow et al., 2003). As shown in human HD 
studies, the YAC128 mice also show cognitive deficits and psychiatric symptoms that 
precede motor deficits.  
1.3.2.4 Knock-in Models 
Knock-in models of HD have a pathogenic CAG repeat expansion knocked-in to 
the endogenous murine huntingtin gene and can be homozygous (HOM) or heterozygous 
(HET) for HD. This is an important aspect when attempting to closely recapitulate the 
genetics of human HD, as homozygosity for the HD mutation is extremely rare. The 
zQ175 mouse model of HD is a knock-in model that contains 175 CAG repeats (Menalled 
et al., 2003; Menalled et al., 2012). At approximately 30 and 38 weeks of age, HOM and 
HET mice exhibit poor rotarod performance, respectively, indicative of a significant 
motor deficit (Menalled et al., 2012). When trained in the procedural two-choice swim 
test, there was only a deficit shown in HOM Q175 mice at 58 weeks of age and no 
significant performance decline in HET mice (Menalled et al., 2012).   
In zQ175 HET mice, the HD-like phenotype is subtle and in some cases, difficult 
to assess using conventional behavioural tests. To increase phenotypic severity of the 
zQ175 model, zQ175 mice were backcrossed with FVB/N mice to create the Q175F line 
(Southwell et al., 2016). Then, mice with cre recombinase were crossed with Q175F mice 
to excise a neo cassette, which interferes with gene expression (Pham et al., 1996). The 
end product was the Q175FDN mouse line (Southwell et al., 2016). Similar to the zQ175 
model, the Q175FDN mice express the full HTT gene. The main difference between the 
two knock-in models is that the Q175FDN model displays the triad of HD symptoms as 
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HETs, thereby recapitulating the genetics of human HD. A brief summary of the HD 
mouse models listed is provided in Table 1.1  
1.3.3 Glutamate uptake and GLT-1 in HD  
The biochemical uptake assay was used in the R6/2 mice at 8-12 weeks of age and 
suggested an impairment in glutamate uptake in the striatum and cortex that correlated 
with a decrease in GLT-1 mRNA and protein expression (Liévens et al., 2001). This 
change in GLT-1 mRNA expression occurred before any evident neurodegeneration and 
was suggested to cause an impairment in glutamate uptake. Furthermore, these results 
were replicated by other researchers who used the biochemical uptake assay (Behrens et 
al., 2002; Shin et al., 2005; Estrada-Sanchez et al., 2009) and no net-flux microdialysis 
(Miller et al., 2008). In YAC128 mice there was no reduction in GLT-1 expression but 
the transporters exhibited reduced palmitoylation, which greatly reduced their efficiency 
(Huang et al., 2010).  
In contrast, when using iGluSnFR and STCs, Parsons et al. (2016) saw no 
evidence of glutamate uptake impairment in YAC128 mice and even found accelerated 
glutamate uptake in the R6/2 mouse model. As the biochemical uptake assay involves 
working with synaptosomes, which has been shown to overemphasize neuronal uptake  
(Petr et al., 2015), it is important to use a method that can measure glutamate uptake 
while keeping synapses intact to further explore the excitotoxic hypothesis of HD. 
Interestingly, a recent study using iGluu, an ultrafast sensor of glutamate, found that 
glutamate uptake in the vicinity of select cortico-striatal axon terminals was indeed 
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Table 1.1 Summary of HD mouse models. Presented here is an overview of some of the 
most commonly used HD mouse models summarizing when motor, cognitive, and 
psychiatric symptoms develop as well as how they express HD.  
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Mouse Model Motor 
Symptoms 
Cognitive 
Symptoms 
Psychiatric 
Symptoms 
How HD is 
Expressed  
R6/1 ~7 months of 
age (Harrison 
et al., 2013) 
~3 months of age 
(Nithianantharajah 
et al., 2008) 
~3 months of 
age (Pang et 
al., 2008) 
N-terminal 
fragment only 
R6/2 ~2 months of 
age (Lione et 
al., 1999) 
~1-2 months of 
age (Lione et al., 
1999) 
~1.5 months 
of age (File, 
Mahal, 
Mangiarini, & 
Bates, 1998) 
N-terminal 
fragment only 
YAC128 ~6 months of 
age (Slow et 
al., 2003) 
~8 months of age 
(Van Raamsdonk 
et al., 2005) 
~3 months of 
age (Pouladi et 
al., 2009) 
Yeast artificial 
chromosome 
containing 128 
CAG repeats 
zQ175 HOM: ~8 
months; HET: 
~9.5 months 
(Menalled et 
al., 2012) 
HOM: ~13 
months; HET: 
N/A 
(Menalled et al., 
2012) 
HOM: ~2 
months; 
HET:~20 
weeks 
(Menalled et 
al., 2012) 
CAG repeats 
knocked-in 
Q175FDN HOM: ~6 
months; HET; 
~8 months 
(Southwell et 
al., 2016) 
HOM: ~3-6 
months; HET; ~6-
9 months 
(Southwell et al., 
2016) 
HOM: ~3 
months; HET; 
~6 months 
(Southwell et 
al., 2016) 
CAG repeats 
knocked-in 
without gene 
suppressing 
neocassette 
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impaired in Q175 mice; this effect was replicated in WT mice when both EAAT1 and 
GLT-1 was blocked (Dvorzhak et al., 2019). There was also a reduction of GLT-1 around 
the synaptic terminals which is thought to contribute to the glutamate uptake impairment 
in the Q175 mice (Dvorzhak et al., 2019). However, when GLT-1 was further reduced in 
the R6/2 model by small interfering RNA (siRNA), there was no increase in disease 
progression or severity (Petr et al., 2013). In all, the precise contribution of glutamate 
transporter dysfunction to HD neurobiology remains ambiguous.  
1.3.4 Long-Term Potentiation (LTP) and HD 
 Long-term potentiation (LTP; Bliss & Lømo, 1973) is the activity-dependent 
strengthening of synapses that underlies the process of learning and memory (Bliss & 
Collingridge, 1993; Whitlock et al., 2006). The Schaffer collateral pathway (CA1-CA3 
synapses) is the most commonly used pathway to study LTP. One form of LTP is 
NMDAR-dependent LTP which requires the depolarization of the postsynaptic cell to 
remove the Mg2+ from NMDARs. This causes an increase in Ca2+ concentration in the 
post-synaptic cell and activates various intracellular kinases including calmodulin-
dependent protein kinase (CaMKII). CaMKII phosphorylates the transmembrane 
AMPAR regulatory protein (TARP) which causes an increase in synaptic AMPARs (Park 
et al., 2016).  
 Two commonly used protocols to induce NMDAR-dependent LTP include high 
frequency stimulation (HFS) and theta burst stimulation (TBS). HFS is a stimulation 
protocol consisting of 1 second pulses delivered at 100 Hz (Yun et al., 2002) while TBS 
typically involves 10 bursts of 4 pulses with 200 ms between each burst (Perez et al., 
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1999). Interestingly, when the proteins involved in HFS-LTP and TBS-LTP consolidation 
were compared, it was found that each protocol required different proteins to induce LTP 
(Zhu et al., 2015). Thus, numerous patterns of activity can result in NMDAR-dependent 
LTP through the recruitment of intracellular signaling pathways that are specific to the 
method of induction.  
Up until recent years, the corticostriatal circuit was the focus as the source of 
cognitive deficits in HD (Bäckman et al., 1997; Cayzac et al., 2011).  For example, in pre-
symptomatic R6/1 mice, an in vivo study measured cell firing in the corticostriatal 
pathway while the mice performed a procedural learning memory task (Cayzac et al., 
2011).  These researchers found that there was a diminished recruitment of striatal cells 
during the task which was associated with cognitive deficits (Cayzac et al., 2011).  
However, the hippocampus, a brain region involved in learning and memory, also 
displays significant degeneration in HD human brain tissue (Rosas et al., 2003; Begeti et 
al., 2016).   
Numerous studies have reported LTP deficits in several mouse models of HD. In 
1999, Usdin et al. engineered a knock-in mouse model of HD containing approximately 
80 CAG repeats and found that these mice exhibited deficits in CA3-CA1 hippocampal 
LTP compared to WT controls. Furthermore, research evaluating LTP deficits in the R6/2 
(Murphy et al., 2000), R6/1 (Giralt et al., 2009), and YAC72 models (Hodgson et al., 
1999) all show significant impairments in LTP. Excessive glutamate has been shown to 
cause LTP deficits (Li et al., 2011) and could be an underlying mechanism of the LTP 
deficits in HD. Therefore, we sought to uncover if there is a glutamate uptake impairment 
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in the HD hippocampus and examine if  increasing GLT-1 expression may be able to 
restore LTP deficits to WT levels.   
1.4 Pharmacological ways to increase GLT-1 expression 
In 2005, Rothstein et al. conducted a blind drug screening to find a pharmaceutical 
that could increase GLT-1 protein expression. They determined that ceftriaxone, a beta-
lactam antibiotic, had the greatest impact on GLT-1 expression and was neuroprotective 
when used in disease models of Amyotrophic Lateral Sclerosis (ALS) and epilepsy. In a 
mouse model of AD, ceftriaxone increased GLT-1 expression and glutamate clearance 
surrounding amyloid beta plaques (Hefendehl et al., 2016). Furthermore, ceftriaxone was 
able to alleviate motor symptoms in the R6/2 mouse model (Miller et al., 2008). 
However, its effect on cognitive symptoms in HD has yet to be researched.   
Recently, a drug called LDN/OSU-0212320 (LDN) was developed and can also 
increase GLT-1 protein expression. LDN treatment has been shown to slow disease 
progression in a mouse model of ALS and prevent the frequency of seizures in a mouse 
model of epilepsy (Kong et al., 2014).  In a mouse model of AD, LDN treatment restored 
cognitive function and synaptic integrity which continued for up to one month after 
treatment cessation (Takahashi et al., 2015). Both ceftriaxone and LDN are promising in 
their ability to upregulate GLT-1 and potentially increase glutamate clearance. However, 
as described above, transporter expression levels do not necessarily correlate linearly with 
glutamate uptake rates, and functional glutamate uptake is rarely quantified following 
ceftriaxone or LDN treatment.  
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1.5 Aims and Hypothesis 
 In the present thesis, we used iGluSnFR to demonstrate that under certain patterns 
of neural activity, a glutamate uptake deficit can be observed in the hippocampus of 
Q175FDN mice. We hypothesized that ceftriaxone treatment would restore glutamate 
clearance rates and synaptic plasticity deficits to WT levels. Interestingly, ceftriaxone had 
no effect on clearance rates in this study. The surprising results of this first study 
prompted a second study in which we tested the functional effects of ceftriaxone and 
LDN on glutamate dynamics in multiple brain regions of healthy wild-type mice.  
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Chapter 2 Materials and Methods 
2.1 Animals and Drugs 
 For experiment 1, we used the Q175FDN knock-in model of HD (N=9; Southwell 
et al., 2016) and their WT littermates (N=13), both males and females.  These mice were 
bred from 4 breeding pairs at Memorial University in the Animal Care facility using a 
HET and WT mating paradigm which produces WT (50%) and HET (50%) mice.  Mice 
were housed in ventilated cage racks in groups of 3-4 and kept on a 12:12 light, dark 
cycle with ad libitum food and water.  At approximately 5 months of age, stereotaxic 
surgery was performed on the mice and they were housed separately.  Mice in the 
ceftriaxone (concentration of 10mg/ml) group received intraperitoneal injections of 
200mg/kg a day for 7 days while the saline cohort received 0.5-1ml 0.9% saline a day for 
7 days.   
For experiment 2, 32 WT male FVB mice were ordered from Charles River at 22 
days of age.  They were housed in ventilated cage racks in groups of 3-4 and kept on a 
12:12 light, dark cycle with ad libitum food and water.  After acclimatization (minimum 
three days after arrival), stereotaxic surgery was performed on the mice and they were 
housed separately.  Mice were divided into four cohorts: ceftriaxone (N=7), saline (N=7), 
LDN (N=9), and vehicle (N=9).  Mice in the ceftriaxone (concentration of 10mg/ml) 
group received i.p. injections of 200mg/kg a day for 5-7 days while the saline cohort 
received 0.5-1ml 0.9% saline a day for 5-7 days.  Mice in the LDN group were i.p. 
injected once with 40mg/kg and the vehicle group injected once with 0.5ml of vehicle 
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solution (1% Dimethylsulfoxide (DMSO), 1% polyethylene glycol 400, 0.2% Tween 80, 
10% hydroxypropyl-β-cyclodextrin. 10% saline). 
2.2 Stereotaxic Surgery 
 For both experiments, mice were anesthetized by isoflurane inhalation (3%) and 
maintained with 1.5-2% isoflurane for the duration of the surgical procedure. Mice were 
secured within the ear bars of a standard stereotaxic apparatus (Stoelting), eye drops were 
used to keep the eyes lubricated throughout the procedure and a 0.5 ml subcutaneous 
(s.c.) injection of 0.9% sterile saline containing 2 mg/kg meloxicam was provided. When 
unresponsive to toe-pinch, a small amount of fur above the scalp was cut with a pair of 
scissors and 0.2 ml of 0.2% lidocaine was injected (s.c) above the skull. A small incision 
was then made in the scalp around bregma, and the underlying skull was exposed. Next, a 
hand drill was used to thin the skull at the desired co-ordinates from bregma to expose the 
underlying cortex while minimizing tissue damage. A Neuros 7002 Hamilton Syringe was 
attached to an infusion pump (Pump 11 Elite Nanomite, Harvard Apparatus) which was 
then secured to the stereotaxic frame.  
For experiment 1, a total volume of 1 μl of pAAV.hSyn.iGluSnFr.WPRE.SV40 
(syn-iGluSnFR; Addgene, catalogue number 98929-AAV1) was injected into the 
hippocampus with coordinates of: 2.6 mm posterior, 2.4 mm lateral (right), 1.2 and 1.4 
mm ventral to brain surface. We used two ventral coordinates to ensure that the CA3-
CA1 region of the hippocampus would be exposed to the virus and express iGluSnFR. At 
the end of every surgery, the syringe was slowly withdrawn, the incision was sutured and 
mice were injected with 0.5 ml 0.9% saline (s.c.) before being placed on a heating pad for 
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approximately 30 minutes to accelerate recovery. For experiment 2, a total volume of 1 μl 
of pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 (GFAP-iGluSnFR; Addgene, catalogue 
number 98930-AAV1) was injected into the cortex, hippocampus, or striatum at an 
injection rate of 5 nl/s. The syringe was left in place for an additional 5 minutes following 
the injection. The following co-ordinates were used with respect to bregma: cortex, – 0.7 
mm anterior, 2.0 mm lateral (right), 0.6 mm ventral; hippocampus, – 2.6 mm posterior, 
2.4 mm lateral (right), 1.2 and 1.4 mm ventral to brain surface; striatum, – 0.7 mm 
anterior, 2.0 mm lateral (right), 2.6 mm ventral to brain surface.  
2.3 Slice Preparation 
For experiment 1, mice were aged to 6 months +/- 2 weeks, an age where the HD-
phenotype begins to emerge in Q175FDN heterozygous mice (Southwell et al., 2016), 
and were injected (i.p.) for 7 days with ceftriaxone 2-4 weeks following iGluSnFR 
injections. For experiment 2, mice were i.p. injected for 5-7 days with ceftriaxone or once 
with LDN at 2-4 months of age (2-4 weeks following iGluSnFR injections). All mice 
were anesthetized using isoflurane and decapitated 24 hours after the last injection. The 
brain was quickly removed and placed in ice-cold oxygenated (95% O2/5% CO2) slicing 
solution consisting of 125mM NaCL, 2.5mM KCl, 25mM NaHCO3 , 1.25mM NaH2PO4, 
2.5 mM MgCl2, 1.5mM CaCl2, 10mM D-(+)-Glucose. Transverse sections (350 um) 
containing the hippocampus and coronal sections (350 um) containing the cortex, 
hippocampus, and striatum  were cut using a Leica VT1000 S vibratome for experiment 1 
and 2, respectively. Slices were then incubated at room temperature in oxygenated 
artificial cerebral spinal fluid (ACSF) composed of 125mM NaCL, 2.5mM KCl, 25mM 
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NaHCO3 , 1.25mM NaH2PO4, 1.0mM MgCl2, 2.0mM CaCl2, 10mM D-(+)-Glucose. 
Slices were left to recover in ACSF for at least 90 or 45 minutes before electrophysiology 
or imaging experiments, respectively. 
2.4 Imaging and image analysis 
All slices used for imaging were transferred to a recording chamber under an 
Olympus BX-61 microscope, and a peristaltic pump (MP-II, Harvard Apparatus) was 
used to perfuse oxygenated ACSF at a flow rate of 1-2 ml/min. ACSF was heated to 32 
°C using an in-line heater and temperature controller (TC-344C, Harvard Apparatus). 
Glass stimulating electrodes were pulled using a Narishige PB-7 pipette puller to a 
resistance of 1-2 MΩ when filled with ACSF. The stimulating electrode was placed in the 
Schaffer collateral (CA3-CA1) pathway within the stratum radiatum of the hippocampus 
for experiment 1. For experiment 2 the electrode was placed in the deep layers (layer IV 
and V) of the cortex, the Schaffer collateral pathway of the hippocampus, and in the 
dorsal part of the striatum. In each experiment, the glass electrode was placed at a depth 
of approximately 50-100 μm below the slice surface.  
Clampex software (Molecular Devices) was used to send TTL triggers through the 
digital outputs of a Digidata 1550A (Molecular Devices) for precise control over a LED 
illumination source (Prior, Lumen 300), an EM-CCD camera (Andor, iXon Ultra 897) 
and an Iso-flex stimulus isolator (AMPI). iGluSnFR responses to evoked neural activity 
were recorded with Andor Solis software, using 4x4 binning and an acquisition rate of 
205 frames per second. For experiment 1, high frequency stimulation (HFS; 100 pulses at 
100 Hz) and theta burst stimulation (TBS; 10 bursts of 4 pulses at 50 Hz) each consisted 
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of one stimulus and one non-stimulus trial with stimulation trials bleach corrected in Fiji. 
An average of the bleach corrected stimulus trials was created using the IOS and VSD 
signal processor plugin. For experiment 2, evoked iGluSnFR responses for 2-50 pulses 
were averaged over 5 trials, with non-stimulus trials interleaved to control for any 
bleaching of the iGluSnFR signal during acquisition. The non-stimulus trials were 
averaged in ImageJ and subtracted from the average of the stimulus trials using the IOS 
and VSD signal processor plugin. For each experiment, the dynamics of extracellular 
glutamate dynamics within a given field was determined by calculating the average 
fluorescence intensity within a 10 x 10 pixel ROI (1 pixel at 4x4 binning = 15.6 μm) 
placed adjacent to the location of the stimulating electrode. Values for %ΔF/F were 
copied to GraphPad Prism and Microsoft Excel for further analysis.  
2.5 Electrophysiology for experiment 1 (HFS LTP) 
 After the recovery period, a slice containing transverse hippocampus was placed 
in a MED64 multi-electrode probe filled with oxygenated ACSF. The slice was 
positioned on an 8x8 array of 64 electrodes using a Plugable 250x digital USB camera. 
Once positioned with electrodes contacting the CA3 and CA1 sub regions of the 
hippocampus, the probe was placed into the MED64 connector and perfused with 
oxygenated ACSF run through a peristaltic pump. The slice was left in the system to 
acclimatize for 15 minutes before stimulation.  
After 15 minutes an electrode that was positioned within the Shaffer Collateral 
projection from CA3-CA1 was selected to be the stimulating electrode. Mobius software 
was used to monitor responses in the remaining 63 electrodes. An input/output curve was 
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performed by inducing field excitatory postsynaptic potentials (fEPSP) starting at 10 μA 
and increasing in 5 μA increments to determine the stimulation intensity that elicited 30-
40% of the maximal fEPSP response. This stimulation intensity determined from the 
input/output curve was used to stimulate the slice for plasticity experiments.  
The slice was then stimulated with single pulses (0.2 ms width) every 20 seconds.  
The consequential response was monitored by the remaining 63 electrodes, until a stable 
baseline was present for 10 consecutive minutes. After a stable baseline was achieved, 
high frequency stimulation (HFS; Bliss & Collingridge, 1993) was applied to induce 
long-term potentiation (LTP). HFS consists of 100 pulses in 1 second. fEPSPs were then 
monitored for 60 minutes following HFS. 
2.6 Western Blots 
For experiment 1 the hippocampus was dissected from 2 transverse sections (350 
µm each) and for experiment 2 the cortex, hippocampus, and striatum were dissected out 
and homogenized in 200-400 μl each of lysis buffer+ containing protease/phosphatase 
inhibitors. Supernatant was collected from each brain region and protein concentration 
was determined using BSA standards. 50 μg of protein from each region was added to 
separate lanes of 10% SDS PAGE gels for electrophoresis in one times electrophoresis 
buffer (100 ml of 10 times electrophoresis buffer and 900 ml distilled water) at 100 volts. 
After the proteins separated on the gel it was placed in one times transfer buffer (100 ml 
of 10 times transfer buffer, 100 ml of methanol, and 800 ml of distilled water) and was 
transferred to a nitrocellulose membrane at 100 volts for one hour. The membrane was 
blocked using 5% milk (5 g of skim milk powder in 100 ml of TBS-T) for one hour. After 
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blocking, primary antibodies for GLT-1 (E1, 1:1,000, Santa Cruz, mouse-monoclonal) 
and Actin (C4, 1:1,000, Santa Cruz, mouse-monocolonal) were used, with actin being a 
loading control and membranes were left in primary antibodies over night at 4 degrees 
Celsius. The next day, goat anti-mouse IgG-HRP secondary antibody (sc-2005, 1:5,000, 
Santa Cruz, monoclonal) was added to the membranes and incubated for 1-2 hours at 
room temperature. Blots were developed using chemiluminescent HRP substrate 
(Millipore, Cat. No. WBKLS0100, Lot No. 1712501) and ImageJ was used to analyze 
and quantify the developed bands to determine GLT-1 expression. 
2.7 Statistics 
 Statistical tests, performed in GraphPad Prism, included two-way repeated-
measures (RM) ANOVA, and paired t-test. The statistical test used for each experiment is 
indicated in Results. P values of <0.05 were considered significant. Where indicated, N 
and n refer to the number of animals and slices used in each experiment, respectively. 
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Chapter 3 Results 
3.1 Experiment 1: Treating an animal model of HD with ceftriaxone 
3.1.1 Characterization of extracellular glutamate dynamics in the 
hippocampus during HFS 
 We first examined the effect of the HD-causing mutation on glutamate dynamics 
in the hippocampus as well as the effect of ceftriaxone treatment on glutamate dynamics. 
To quantify glutamate dynamics during neural activity, we challenged the slices with a 
high amount of glutamate release by electrically stimulating the Schaffer collateral 
pathway using HFS (100 pulses, 100 Hz), a commonly-used stimulation paradigm to 
induce LTP (Fig. 3.1A).  Four cohorts of mice were used: WT-Saline (WT-Sal; N=6, 
n=11; Fig.3.1B), HET-Saline (HET-Sal; N=3, n=6; Fig.3.1C), WT-Cef (N=5, n=6; Fig. 
3.1D), and HET-Cef (N=3, n=6; Fig. 3.1E).  We expressed iGluSnFR under control of the 
synapsin promoter to limit iGluSnFR expression to neurons (Marvin et al., 2013); 
therefore, our study focused on the amount and time-course of endogenous glutamate 
transients sensed at the neuronal surface in the hippocampus. Glutamate release and 
clearance rates were visualized in real-time using a high-speed wide field imaging camera 
(205 Hz) in response to HFS (Fig. 3.1A). The relative magnitude of glutamate release was 
measured by peak (Koch et al., 2018) which is the maximum %ΔF/F (Fig. 3.1F), 
clearance was measured by calculating the decay tau from the relative decay in 
fluorescence after stimulation has ended (Pinky et al., 2018; Fig. 3.1G), area under the 
curve (AUC) reflects the total amount of glutamate accumulation during stimulation (Fig. 
3.1 H), and iGluSnFR sustain is how long glutamate stayed in the extracellular space 
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(Fig. 3.1I).  Our results show a significant glutamate clearance impairment in the 
hippocampus of 6 month old Q175FDN mice (Fig. 3.1G, RM ANOVA, ptreatment=0.6080, 
pgenotype<0.05). Furthermore, we found a significant accumulation of glutamate in the 
Schaffer collateral synapses (AUC; Fig. 3.1H, RM ANOVA, ptreatment=0.4245, 
pgenotype<0.001) as well as a significant difference in iGluSnFR sustain (Fig. 3.1I, RM 
ANOVA, ptreatment=0.2463, pgenotype<0.01).   
Interestingly, we demonstrated that ceftriaxone significantly lowered the peak of 
glutamate release in both WT and HD treated animals (Fig. 3.1F, RM ANOVA, ptreatment 
<0.05, pgenotype=0.7454) with ceftriaxone almost halving the magnitude of glutamate 
release (%ΔF/F values).  Conversely, we found that ceftriaxone had no significant effect 
on decay (Fig. 3.1G, RM ANOVA, ptreatment=0.6080), AUC (Fig. 3.1H, RM ANOVA, 
ptreatment=0.4245) or iGluSnFR sustain (Fig. 3.1I, RM ANOVA, ptreatment=0.2463) in the 
hippocampus of WT or HD treated mice.  Together, these results suggest there is a 
buildup of glutamate in the extracellular space in the hippocampus of HD mice that is not 
prevented by ceftriaxone treatment. 
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Figure 3.1 Characterization of glutamate dynamics in the hippocampus during HFS. A, 
representative heat maps of iGluSnFR responses following HFS (100 Hz, 1 s).  Maximum 
projection intensities (peak responses) are shown in the x-y plane (image size = 2 x 
2mm), and the y-z (time) plots show the kinetics of the response in the CA1-CA3 
projection. The white bar represents the stimulation time. B-E, Mean (± SEM) iGluSnFR 
traces in response to HFS for WT-saline (WT Sal; B), HET-saline (HET Sal; C), WT 
ceftriaxone (WT Cef; D), and HET ceftriaxone (HET Cef; E). Responses are normalized 
to their peak. Stimulation time represented by the black bar above the traces. The 
following graphs are grouped data showing mean (± SEM) iGluSnFR response peak (F), 
decay tau (G), total glutamate accumulation shown by area under the curve (AUC; H), 
and iGluSnFR sustain, calculated by dividing %ΔF/F at the end of stimulation by the peak 
of the response (I).  
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3.1.2 Characterization of glutamate dynamics in the hippocampus during 
TBS 
 A second commonly used LTP induction protocol is TBS (Larson & Lynch, 
1986).  While HFS LTP requires adenosine A2A receptors and PKA activation, TBS 
requires calpain-1 and ERK activation (Zhu et al., 2015). In addition to being modulated 
by distinct underlying mechanisms, glutamate levels reached during HFS places more 
pressure on the glutamate transporter system compared to the shorter bursts associated 
with TBS (Pinky et al., 2018). Therefore, we also used TBS to induce LTP and study 
glutamate uptake in each group. We stimulated the Schaffer collateral pathway of each 
group (WT-Sal; N=5, n=6, HET-Sal; N=4, n=7, WT-Cef, N=6, n=8, HET-Cef; N=3, n=5) 
using TBS (10 bursts of 4 pulses at 100 Hz, inter-burst interval of 200 ms; Fig. 3.2A).  
We measured responses of each group (Fig. 3.2B-E) and calculated the peak (Fig. 3.2F) 
and the decay tau at the end of each of the ten bursts associated with TBS (Fig. 3.2G-H).  
We found no differences in peak between WT and HET mice as well as no interaction 
effects (Fig. 3.2F, RM ANOVA, pgenotype=0.3223, pinteraction=0.6368, pburst<0.001).  When 
comparing the decay of WT and HET mice treated with saline, we found no significant 
genotype or interaction effects (Fig. 3.2G, RM ANOVA, pgenotype=0.9853, 
pinteraction=0.1957, pburst<0.05).  Similarly, when comparing the decay of WT and HET 
mice treated with ceftriaxone, there were no significant genotype or interaction effects 
(Fig. 3.2H, RM ANOVA, pgenotype=0.0778. pinteraction=0.7654, pburst=0.2599).  Our results 
suggest that while HFS revealed elevated glutamate accumulation and slower clearance 
rates in the Q175FDN hippocampus, extracellular glutamate dynamics during TBS are 
not significantly different from those observed in WT mice.   
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Figure 3.2 Characterization of glutamate dynamics in the hippocampus during TBS.  A, 
representative heat maps of iGluSnFR responses following TBS stimulation.  Maximum 
projection intensities (peak responses) are shown in the x-y plane (image size = 2x2mm), 
and the y-z (time) plots show the kinetics of the response in the CA1-CA3 projection. 
Burst numbers are above each burst. B-E, Mean (± SEM) iGluSnFR traces in response to 
TBS for WT Sal (B), HET Sal (C), WT Cef (D), and HET Cef (E). (F), grouped data 
showing mean (± SEM) iGluSnFR response peaks. G-H, mean (± SEM) decay tau results 
comparing WT Sal and HET Sal (G) and WT Cef and HET Cef (H).  
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3.1.3 GLT-1 expression in hippocampal tissue from WT and Q175FDN 
mice 
 GLT-1, primarily located on astrocytes, is the brain’s most abundant glutamate 
transporter and makes a substantial contribution to glutamate clearance rates (Danbolt et 
al., 1992; Tanaka et al., 1997; Otis & Kavanaugh, 2000). To determine whether low GLT-
1 expression could explain the alterations in glutamate dynamics observed in Q175FDN 
hippocampal tissue following HFS, we quantified GLT-1 expression using western blot 
(WT Sal; N=5, HET Sal; N=5, WT Cef; N=5, HET Cef; N=5). Two-way ANOVA was 
used to calculate results. We found no significant genotype difference in hippocampal 
GLT-1 levels (Fig. 3.3A, RM ANOVA, pgenotype=0.2457). Surprisingly, we also found that 
ceftriaxone did not increase GLT-1 expression in either genotype (Fig. 3.3A, RM 
ANOVA, ptreatment=0.0913). As much of the research using ceftriaxone tends to be in 
younger rats/mice (Rothstein et al., 2005; Miller et al., 2008), we injected a cohort of two-
three month old WT mice with either ceftriaxone (N=5) or saline (N=5).  In line with 
previous literature, we found that ceftriaxone treatment significantly increased GLT-1 
expression in this cohort of younger, WT mice (Fig. 3.3B, paired t-test; ptreatment<0.05).  
Our results suggest that altered GLT-1 expression is not a cause of altered glutamate 
dynamics seen in the HD hippocampus following HFS. Furthermore, we have uncovered 
an age-dependent effect of ceftriaxone at the dose required to increase GLT-1 expression.  
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Figure 3.3 GLT-1 expression. (A) western blot results from 6 month old WT and HET 
mice injected with either saline or ceftriaxone. (B) Western blot results from 2-3 month 
old WT FVB mice injected with saline or ceftriaxone.  
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3.1.4 HFS LTP experiments 
 In addition to quantifying glutamate dynamics, we also asked whether ceftriaxone 
could restore the LTP impairment known to occur in mouse models of HD (Usdin et al., 
1999; Murphy et al., 2000; Giralt et al., 2009). Based on our iGluSnFR imaging results, 
we found evidence for dysfunctional uptake following HFS but not TBS in the HD 
hippocampus; therefore, we conducted all LTP experiments using HFS as the induction 
protocol (WT-Sal; N=3, n=4, HET-Sal; N=3, n=5, WT-Cef; N=5, n=7, HET-Cef; N=5, 
n=8). We show that in the Q175FDN at this age there was a significant LTP impairment 
in HD mice (Figure A1, RM ANOVA, pgenotype<0.05).  However, we found that 
ceftriaxone did not improve LTP impairments in HD mice. In fact, ceftriaxone 
significantly impaired LTP overall (Appendix A, RM ANOVA, ptreatment<0.05).  These 
results suggest that ceftriaxone is not a beneficial treatment to improve LTP deficits and 
can impair LTP in the healthy brain.   
3.2 Experiment 2: Pharmacologically increasing GLT-1 expression in the healthy 
brain 
After the completion of Experiment 1, we were surprised to see that ceftriaxone 
was unable to increase functional measures of glutamate clearance. The hippocampus is 
already more efficient at clearing glutamate from the extracellular space than other brain 
regions such as the cortex and striatum (Pinky et al., 2018). Thus, it was of interest to 
compare the functional effect of increasing GLT-1 expression in the cortex, hippocampus, 
and striatum in the healthy brain.  
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3.2.1 Glutamate Clearance in the Cortex after GLT-1 Upregulation  
Pinky et al. (2018) demonstrated that glutamate clearance rates vary in an activity- 
and region-dependent manner. Therefore, we selected three brain regions to study the 
functional effects of increasing GLT-1 expression. First, we examined the effect of 
increasing GLT-1 using either ceftriaxone or LDN on glutamate dynamics in the cortex. 
We injected a cohort of mice with ceftriaxone (N=7, n=16) or saline (N=7, n=16) and 
found a significant increase in GLT-1 expression after 5-7 days of ceftriaxone treatment 
(Fig. 3.4A, paired t-test, p=0.0452). Next, we stimulated glutamate release (100 Hz) in the 
deep layers of the cortex with a glass electrode stimulating electrode in control and 
ceftriaxone treated mice (Fig. 3.4B).  As GLT-1 is predominately located on astrocytes, 
we used the GFAP promoter to limit iGluSnFR expression to astrocytes (Marvin et al., 
2013); therefore, our study focuses on the relative amount and time-course of synaptically 
released glutamate sensed at the astrocytic surface.  Glutamate clearance (Fig. 3.4B) was 
visualized in real-time using a high-speed wide field imaging camera (205 Hz) in 
response to increasing challenges of glutamate accumulation (2, 5, 10, 20, 30, 40, and 50 
pulses; 100 Hz). Despite our observation of a significant increase in GLT-1 expression, 
we found that ceftriaxone had no significant effect on glutamate clearance rates (Fig. 
3.4C, RM Two-way ANOVA, ppulses<0.001, ptreatment=0.0828, pinteraction=0.1938). While 
decay taus were not affected, we found that ceftriaxone significantly lowered the response 
peak (Fig. 3.4D, RM Two-way ANOVA, ppulses<0.001, ptreatment=0.0082, pinteraction=0.0062) 
as well as the total amount of glutamate accumulation in the extracellular space, as 
measured by the area under the curve of iGluSnFR responses (Fig. 3.4E, RM Two-way 
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ANOVA, ppulses<0.001, ptreatment=0.0333, pinteraction=0.0044). Thus, in the cortex, 
ceftriaxone treatment reduces extracellular glutamate accumulation during neural activity.  
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Figure 3.4 Characterization of glutamate dynamics in the cortex after ceftriaxone 
treatment. A, western blot results from 2-4 month old male mice injected with either 
saline (N=7) or ceftriaxone (N=7) for 5-7 days. B, representative heat maps and mean (± 
SEM) normalized iGluSnFR responses for 2, 20, and 50 pulses of stimulation (100 Hz).  
Maximum projection intensities (peak responses) are shown in the x-y plane (image size 
= 2 x 2mm), and the y-z (time) plots show the kinetics of the response in the deep layers 
of the cortex. The white bar represents the stimulation time. Mean traces are normalized 
to peak and black bar represents stimulation time. The following graphs are grouped data 
showing mean (± SEM) iGluSnFR decay tau (C), response peak (D), and total glutamate 
accumulation shown by area under the curve (AUC; E).  
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 As ceftriaxone had surprisingly little effect on overall glutamate clearance rates, 
we were interested in assessing another compound known to increase GLT-1 expression, 
LDN, on glutamate dynamics. In line with previous studies (Kong et al., 2014; Takahashi 
et al., 2015), we found that, compared to mice injected with vehicle solution (N=9, n=10), 
LDN (N=9, n=12) significantly increased GLT-1 expression in the cortex (Fig. 3.5A, 
paired t-test, p=0.0484). Again, we stimulated the deep layers of the cortex with a glass 
stimulating electrode to initiate glutamate release (Fig. 3.5B). Despite the increase in 
GLT-1 expression, we found that LDN had no significant effect on iGluSnFR decay taus 
(Fig. 3.5C, RM Two-way ANOVA, ppulses<0.001, ptreatment=0.3459, pinteraction=0.8408). 
Unlike ceftriaxone, we found that LDN had no significant effect on the peak (Fig. 3.5D, 
RM Two-way ANOVA, ppulses<0.001, ptreatment=0.6564, pinteraction=0.7621) or the area 
under the curve (Fig. 3.5E, RM Two-way ANOVA, ppulses<0.001, ptreatment=0.5358, 
pinteraction=0.8545). 
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Figure 3.5 Characterization of glutamate dynamics in the cortex after LDN treatment. A, 
western blot results from 2-4 month old male mice injected with either vehicle (N=9) or 
LDN (N=9) for 1 day. B, representative heat maps and mean (± SEM) normalized 
iGluSnFR responses for 2, 20, and 50 pulses of stimulation (100 Hz).  Maximum 
projection intensities (peak responses) are shown in the x-y plane (image size = 2x2mm), 
and the y-z (time) plots show the kinetics of the response in the deep layers of the cortex. 
The white bar represents the stimulation time. Mean traces are normalized to peak and 
black bar represents stimulation time. The following graphs are grouped data showing 
mean (± SEM) iGluSnFR decay tau (C), response peak (D), and total glutamate 
accumulation shown by area under the curve (AUC; E).  
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3.2.2 Glutamate Clearance in the Hippocampus after GLT-1 Upregulation  
The CA3-CA1 Schaeffer Collateral pathway is the pathway most used to study 
learning and memory in the brain.  First, we injected mice with ceftriaxone to determine 
how upregulating GLT-1 expression in this area affects glutamate dynamics (Fig. 3.6). 
We found that, compared to saline (N=7, n=14) injected mice, ceftriaxone (N=7, n=16) 
significantly increased GLT-1 expression in the hippocampus (Fig. 3.6A, paired t-test, 
p=0.0081). We placed a glass stimulating electrode in the CA3-CA1 area of the 
hippocampus and stimulated glutamate release using 2, 5, 10, 20, 30, 40, 50 pulses (100 
Hz; Fig. 3.6B). Similar to the cortex, we found that ceftriaxone had no significant effect 
on iGluSnFR decay taus (Fig. 3.6C, RM Two-way ANOVA, ppulses<0.001, 
ptreatment=0.1538, pinteraction=0.1900). In addition, ceftriaxone did not significantly affect 
hippocampal iGluSnFR peaks (Fig. 3.6D, RM Two-way ANOVA, ppulses<0.001, 
ptreatment=0.0836, pinteraction=0.3301) or the area under the curve (Fig. 3.6E, RM Two-way 
ANOVA, ppulses<0.001, ptreatment=0.3025, pinteraction=0.5302).  
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Figure 3.6 Characterization of glutamate dynamics in the hippocampus after ceftriaxone 
treatment. A, western blot results from 2-4 month old male mice injected with either 
saline (N=7) or ceftriaxone (N=7) for 5-7 days. B, representative heat maps and mean (± 
SEM) normalized iGluSnFR responses for 2, 20, and 50 pulses of stimulation (100 Hz).  
Maximum projection intensities (peak responses) are shown in the x-y plane (image size 
= 2x2mm), and the y-z (time) plots show the kinetics of the response in the CA1-CA3 
projection. The white bar represents the stimulation time. Mean traces are normalized to 
peak and black bar represents stimulation time. The following graphs are grouped data 
showing mean (± SEM) iGluSnFR decay tau (C), response peak (D), and total glutamate 
accumulation shown by area under the curve (AUC; E).  
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In LDN-treated mice, we found a significant increase in GLT-1 expression in 
hippocampal tissue (Fig. 3.7A, paired t-test, p=0.0496) when compared to saline-injected 
mice (N=9, n=13). Using the same stimulation protocols as above to assess glutamate 
dynamics (Fig. 3.7B), we found that LDN had no significant effect on iGluSnFR decay 
taus (Fig. 3.7C, RM Two-way ANOVA, ppulses<0.001, ptreatment=0.7316, pinteraction=0.1450). 
There was a trending interaction effect that reflects the tendency for decay taus to be 
faster following LDN treatment for longer stimulation lengths (e.g. 40 and 50 pulses); 
however, this did not reach statistical significance. Furthermore, LDN had no significant 
effect on iGluSnFR peak (Fig. 3.7D, RM Two-way ANOVA, ppulses<0.001, 
ptreatment=0.3326, pinteraction=0.2252) or area under the curve in the hippocampus (Fig. 3.7E, 
RM Two-way ANOVA, ppulses<0.001, ptreatment=0.7019, pinteraction=0.7946).   
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Figure 3.7 Characterization of glutamate dynamics in the hippocampus after LDN 
treatment. A, western blot results from 2-4 month old male mice injected with either 
vehicle (N=9) or LDN (N=9) for 1 day. B, representative heat maps and mean (± SEM) 
normalized iGluSnFR responses for 2, 20, and 50 pulses of stimulation (100 Hz).  
Maximum projection intensities (peak responses) are shown in the x-y plane (image size 
= 2x2mm), and the y-z (time) plots show the kinetics of the response in the CA1-CA3 
projection. The white bar represents the stimulation time. Mean traces are normalized to 
peak and black bar represents stimulation time. The following graphs are grouped data 
showing mean (± SEM) iGluSnFR decay tau (C), response peak (D), and total glutamate 
accumulation shown by area under the curve (AUC; E).  
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3.2.3 Glutamate Clearance in the Striatum after GLT-1 Upregulation 
Similar to the cortex and hippocampus, we found that ceftriaxone significantly 
increased GLT-1 expression in the striatum (Fig. 3.8A, paired t-test, p=0.0495, saline; 
N=7, n=17, ceftriaxone; N=7, n=20). We evoked glutamate release in the dorsal striatum 
by electrical stimulation as before (2, 5, 10, 20, 30, 40, and 50 pulses; 100 Hz; Fig. 3.8B). 
Similar to the cortex and hippocampus, we found that treatment with ceftriaxone had no 
significant effect on iGluSnFR decay taus (Fig. 3.8C, RM Two-way ANOVA, 
ppulses<0.001, ptreatment=0.1449, pinteraction=0.9860). We also found no significant effects of 
ceftriaxone on the peak (Fig. 3.8D, RM Two-way ANOVA, ppulses<0.001, 
ptreatment=0.9816, pinteraction=0.9995) or total glutamate accumulation, as measured by the 
area under the curve (Fig. 3.8E, RM Two-way ANOVA, ppulses<0.001, ptreatment=0.8684, 
pinteraction=0.9995).  
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Figure 3.8 Characterization of glutamate dynamics in the striatum after ceftriaxone 
treatment. A, western blot results from 2-4 month old male mice injected with either 
saline (N=7) or ceftriaxone (N=7) for 5-7 days. B, representative heat maps and mean (± 
SEM) normalized iGluSnFR responses for 2, 20, and 50 pulses of stimulation (100 Hz).  
Maximum projection intensities (peak responses) are shown in the x-y plane (image size 
= 2x2mm), and the y-z (time) plots show the kinetics of the response in the dorsal 
striatum. The white bar represents the stimulation time. Mean traces are normalized to 
peak and black bar represents stimulation time. The following graphs are grouped data 
showing mean (± SEM) iGluSnFR decay tau (C), response peak (D), and total glutamate 
accumulation shown by area under the curve (AUC; E).  
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In LDN-treated mice (Fig. 3.9), we also found a significant increase in GLT-1 
expression in the striatum (Fig. 3.9A, paired t-test, p=0.0228; vehicle; N=9, n=14, LDN; 
N=9, n=14). We used the same stimulation protocol in the dorsal striatum (Fig. 3.9B) and 
again found no significant effects of LDN on iGluSnFR decay (Fig. 3.9C, RM Two-way 
ANOVA, ppulses<0.001, ptreatment=0.3843, pinteraction=0.9620), peak (Fig. 3.9D, RM Two-
way ANOVA, ppulses<0.001, ptreatment=0.8115, pinteraction=0.9979), or area under the curve 
(Fig. 3.9E, RM Two-way ANOVA, ppulses<0.001, ptreatment=0.9493, pinteraction=0.9991). In 
all, these data suggest that increasing GLT-1 expression has a surprisingly little effect on 
functional measures of glutamate dynamics.   
  
59 
 
Figure 3.9 Characterization of glutamate dynamics in the striatum after LDN treatment. 
A, western blot results from 2-4 month old male mice injected with either vehicle (N=9) 
or LDN (N=9) for 1 day. B, representative heat maps and mean (± SEM) normalized 
iGluSnFR responses for 2, 20, and 50 pulses of stimulation (100 Hz).  Maximum 
projection intensities (peak responses) are shown in the x-y plane (image size = 2x2mm), 
and the y-z (time) plots show the kinetics of the response in the CA1-CA3 projection. The 
white bar represents the stimulation time. Mean traces are normalized to peak and black 
bar represents stimulation time. The following graphs are grouped data showing mean (± 
SEM) iGluSnFR decay tau (C), response peak (D), and total glutamate accumulation 
shown by area under the curve (AUC; E).  
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Chapter 4 Discussion 
4.1 Using ceftriaxone to treat the Q175FDN mouse model of HD 
 Hundreds of studies have used ceftriaxone to increase GLT-1 expression and have 
used methods such as NMDA currents (Shen et al., 2014), microdialysis (Miller et al., 
2008), and the biochemical uptake assay (Shen et al., 2014; Hu et al., 2015) to measure 
glutamate clearance. In contrast to these methods,iGluSnFR is a useful tool that allows 
one to directly visualize glutamate dynamics in situ in response to different electrical 
stimulations.  Using microdialysis, Miller et al. (2008) found that treating the R6/2 model 
of HD alleviated motor symptoms; however, the effect of ceftriaxone on cognitive 
symptoms in HD remain largely unstudied.  Cognitive impairments are regarded as the 
most burdensome symptoms by caregivers and loved ones and can appear 10-15 years 
before motor symptoms (Paulsen, 2011); therefore, it is imperative to find a possible 
treatment that could alleviate these cognitive deficits.  In our study, we used iGluSnFR 
and wide-field imaging to study glutamate dynamics in WT and HD animals with and 
without ceftriaxone treatment during two common LTP induction protocols: HFS (Bliss 
& Collingridge, 1993) and TBS (Larson & Lynch, 1986).   
4.1.1 Glutamate Dynamics in the Hippocampus during HFS and TBS 
stimulation   
We used iGluSnFR to visualize glutamate dynamics in response to synaptic 
stimulation to demonstrate a glutamate clearance impairment in a brain region involved in 
learning and memory; the hippocampus.  During HFS (100 bursts in 1 second) in HD 
mice, we saw a significant impairment in glutamate clearance as well as a significant 
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increase in total glutamate accumulation in the hippocampus which was not alleviated by 
ceftriaxone treatment.  Our results support other studies that show that hippocampal 
function is affected by the HD-causing mutation (Usdin et al., 1999; Gil et al., 2005; 
Lynch et al., 2007; Duff et al., 2010; Paulsen et al., 2013; Kolodziejczyk et al., 2014) and 
may contribute to cognitive deficits associated with HD.   
We found that ceftriaxone had an effect on our peak response to HFS by 
decreasing the maximum amount of glutamate that accumulated in response to trains of 
electrical stimulation.  Recently, it was found that ceftriaxone also upregulates xCT 
expression (Knackstedt et al., 2010), the catalytic subunit of system xc−, which is 
important in maintaining ambient glutamate levels (Baker et al., 2002).  This system 
pumps out one molecule of glutamate per one molecule of cystine it takes in and this 
glutamate activates mGluRs 2/3 on the presynaptic membrane (Baker et al., 2002), which 
has been shown to suppress excitatory neurotransmission (Dietrich et al., 2002).  
Therefore, in our study, ceftriaxone treatment could be increasing xCT expression and 
ambient glutamate levels which could be activating presynaptic mGluRs 2/3 and lowering 
the relative amount of glutamate released in response to HFS.  Interestingly, although we 
observed a ceftriaxone-induced decrease in evoked iGluSnFR peaks, slow glutamate 
clearance and increased glutamate accumulation was observed in HD mice regardless of 
treatment, suggesting that glutamate clearance could be dysfunctional in the HD 
hippocampus and that ceftriaxone treatment has no beneficial effect.   
Unlike HFS, we found no genotype differences in glutamate dynamics in response 
to TBS.  While both HFS and TBS result in the release of large amounts of glutamate, the 
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protocols are different: HFS uses 1 burst of 100 pulses over 1 second while TBS is 10 
bursts of 4 pulses every 200 ms for 1 second.  It has been shown that glutamate 
transporters in the hippocampus become overwhelmed at 100 pulses (100 Hz), as seen in 
HFS, but not at lower pulses such as 5 or fewer pulses, as seen in TBS (Diamond & Jahr, 
2000; Pinky et al., 2018).  Therefore, even in HD, glutamate transporters may still be 
functional enough to clear glutamate after lower pulses compared to higher pulses and 
could explain why no deficiencies in glutamate clearance were found.   
4.1.2 Ceftriaxone does not Alleviate LTP Impairments in HD and Impairs 
LTP in WT Mice 
 For robust NMDAR-dependent LTP to occur there must be the activation of 
synaptic NMDARs (Lu et al., 2001).  Conversely, activation of extrasynaptic NMDARs 
can impair LTP (Li et al., 2011) and LTP impairments are frequently shown in mouse 
models of HD (Usdin et al., 1999; Lynch et al., 2007; Kolodziejczyk et al., 2014). 
Milnerwood et al. (2010) show that in the early HD striatum of YAC128 mice there is an 
increase of extrasynaptic NMDAR expression, and the data in the present thesis suggests 
that HD mice may be vulnerable to excessive glutamate spill-over outside of the synapse 
during HFS. We demonstrate that in the Q175FDN knock-in model of HD (Southwell et 
al., 2016), there was an impairment of HFS-induced LTP at 6 months. It is possible that 
the observed LTP deficit was due to slow glutamate clearance which lead to excessive 
activation of extrasynaptic NMDARs. Unfortunately, ceftriaxone was unable to restore 
healthy LTP in Q175FDN mice.  
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 Surprisingly, not only did ceftriaxone fail to restore Q175FDN LTP to control 
levels, it also impaired LTP in the healthy brain.  AMPAR surface diffusion plays an 
important role in LTP at CA3-CA1 synapses of the hippocampus and if AMPARs are 
immobilized LTP is impaired (Penn et al., 2017).  Ceftriaxone was found to upregulate 
xCT expression (Knackstedt et al., 2010) which affects postsynaptic AMPA receptor 
abundance in the hippocampus (Williams & Featherstone, 2014).  Therefore, it is possible 
that at the Schaffer collateral pathway of the hippocampus, ceftriaxone treatment results 
in the immobilization of AMPARs on the surface of synapses which impairs LTP.   
4.1.3 Ceftriaxone did not increase GLT-1 expression in aged animals  
Surprisingly, we found that ceftriaxone failed to increase GLT-1 expression in the 
hippocampus of both WT and HET mice. Past research has shown a decrease in striatal 
GLT-1 expression that correlates with disease progression in HD mice (Miller et al., 
2008; Estrada-Sánchez et al., 2009; Faideau et al., 2010) while other research has shown 
that GLT-1 protein expression is normal in HD (Huang et al., 2010).  In both the striatum 
and the cortex, Huang et al. (2010) used the biochemical uptake assay to demonstrate a 
glutamate clearance impairment in the YAC128 model of HD that was not due to altered 
GLT-1 expression.  Instead, these researchers found that GLT-1 was dysfunctional due to 
reduced palmitoylation of GLT-1.  When palmitoylation was inhibited in WT mice they 
found a decrease in glutamate clearance, showing that palmitoylation is essential for 
GLT-1 function.  We demonstrate that at this age in the hippocampus of Q175FDN mice 
there is no difference in GLT-1 expression compared to WT mice.  Therefore, it is 
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possible that the altered glutamate dynamics we detected in the HD hippocampus 
following HFS is a result of GLT-1 depalmitoylation rather than low expression levels.   
Finally, we demonstrated an age-dependent effect of ceftriaxone on GLT-1 
expression.  Most research using ceftriaxone to increase GLT-1 expression uses younger 
mice; for example, the initial paper by Rothstein et al. (2005) used cultures from postnatal 
day 9 rats as well as mice aged 70 days old and Miller et al. (2008) used WT and R6/2 
mice that were 6 weeks of age.  Therefore, we injected a younger WT cohort with saline 
or ceftriaxone to compare to the 6 month old mice and we found that ceftriaxone 
increased GLT-1 expression in younger mice.  Ceftriaxone upregulates GLT-1 through 
the activation of nuclear factor-kappa B (NF- κB) which increases the transcription of the 
SLC1A2 gene (Lee et al., 2008).  As animals get older NF- κB activation drives the aging 
process (Adler et al., 2007; Tilstra et al., 2011) and could affect gene transcription.  In the 
hypothalamus in particular, NF- κB activation contributes to whole organism aging and as 
the mice grew older NF- κB activation in the hypothalamus increased (Zhang et al., 
2013).  Therefore, in the older age we used for our mice, it is possible that aging-induced 
differences in NF- κB signaling prevented the typically-observed ceftriaxone-induced 
increase in GLT-1.    
4.2 Pharmacologically increasing GLT-1 expression in the brain 
For decades, GLT-1 has been thought to be the most important transporter 
involved in glutamate clearance and has been suggested to be an important therapeutic 
target for various neurodegenerative diseases including HD (Miller et al., 2008; Estrada-
Sánchez et al., 2009), epilepsy (Tanaka et al., 1997; Petr et al., 2015), and Alzheimer 
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Disease (Takahashi et al., 2015; Hefendehl et al., 2016). Ceftriaxone and LDN are two 
compounds capable of upregulating GLT-1 expression and have shown promising results 
of increasing glutamate clearance (Kong et al., 2014; Shen et al., 2014; Hu et al., 2015). 
However, these results were obtained using the biochemical uptake assay which has been 
criticized for lacking physiological relevance (Petr et al., 2015). Furthermore, in the first 
part of our study, ceftriaxone showed an age-dependent effect on GLT-1 upregulation in 
WT mice. Therefore, we wanted to understand if increasing GLT-1 expression can 
increase real-time endogenous glutamate clearance in three different brain regions of 
younger, WT mice. Here, we use iGluSnFR to visualize glutamate dynamics in real-time 
after treatment with ceftriaxone or LDN to determine if increasing GLT-1 expression can 
result in an increase of glutamate clearance in acute brain slices.     
4.2.1 Ceftriaxone Treatment to Increase GLT-1 Expression 
 It has been over a decade since the landmark study conducted by Rothstein et al. 
(2005) which  placed ceftriaxone as the quintessential drug to enhance glutamate 
clearance for both experimental and/or therapeutic purposes in diseases associated with 
GLT-1 reduction. Ceftriaxone has shown neuroprotective effects in vivo which is thought 
to be due to its ability to increase GLT-1 expression and, by extension, glutamate 
clearance. For example, the SOD1(G93) mouse model of amyotrophic lateral sclerosis 
(ALS), ceftriaxone increased life expectancy and slowed disease progression (Rothstein 
et al., 2005). However, while most studies report that ceftriaxone treatment is beneficial, 
there are some studies that have cited no effect or negative side effects. When ceftriaxone 
was retested in the SOD1(G93A) mouse model, there was no benefit of ceftriaxone 
67 
 
treatment on disease progression (Scott et al., 2008). Furthermore, a clinical trial using 
ceftriaxone to treat individuals with ALS was stopped as there was no early preclinical 
efficacy found of the treatment (Cudkowicz et al., 2014). Omrani et al. (2009) found that 
ceftriaxone treatment significantly impaired long-term depression (LTD), the weakening 
of synaptic connections, in the mossy fibers of the hippocampus, and a study conducted 
by Matos-Ocasio et al. (2014) found that treating WT rats with ceftriaxone impaired their 
performance on the novel object recognition test, a hippocampal-dependent spatial 
learning task (Barker & Warburton, 2011). Due to these conflicting results, it is important 
to further understand the functional effects of ceftriaxone treatment throughout the brain.  
Surprisingly, we found that ceftriaxone had little effect on iGluSnFR 
measurements of functional glutamate clearance in multiple brain regions. In fact, there 
was a slight trend, particularly in the cortex, towards slower glutamate clearance. Slowing 
glutamate clearance would allow for glutamate to remain in the extracellular space longer 
which is thought to impair LTP (Li et al., 2011) and lead to cell death (Hardingham & 
Bading, 2010; Parsons & Raymond, 2014). Huang et al. (2010) found that palmitoylation 
is an important posttranslational modification that is necessary for GLT-1 to be 
functional. It is possible that ceftriaxone increased GLT-1 expression by inserting 
dysfunctional transporters that are missing this important posttranslational modification. 
If dysfunctional transporters were inserted, rather than clearing glutamate, they could 
potentially act as a glutamate buffer, thereby delaying clearance. Furthermore, an 
important aspect of the ability of GLT-1 to clear glutamate is its mobilization across the 
synapse (Murphy-Royal et al., 2015). When GLT-1 was immobilized, there were slower 
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kinetics associated with excitatory postsynaptic currents, which could reflect prolonged 
glutamate times (Murphy-Royal et al., 2015). Therefore, it is also possible that 
ceftriaxone could be affecting GLT-1 mobilization in each brain region.  
An interesting result we uncovered is that ceftriaxone treatment caused a decrease 
in the peak of the response in the cortex and trended to lower the peak in the 
hippocampus. It is unlikely that the reduced glutamate accumulation in these cases is a 
result of more efficient uptake, as accelerated decay kinetics were not observed. 
Ceftriaxone increases GLT-1 expression transcriptionally by activating the NF- κB 
pathway (Lee et al., 2008) which is important in regulating other genes and not just the 
SLC1A2 gene that encodes for the GLT-1 protein. Recently, it was found that ceftriaxone 
also upregulates xCT expression (Knackstedt et al., 2010), the catalytic subunit of system 
xc−, which is important in maintaining ambient glutamate levels (Baker et al., 2002).  
This system pumps out one molecule of glutamate per one molecule of cystine it takes in. 
The glutamate it pumps out activates mGluRs 2/3 on the presynaptic membrane (Baker et 
al., 2002) which have been shown to suppress excitatory neurotransmission (Dietrich et 
al., 2002).  Therefore, over the course of ceftriaxone treatment, it is possible that there is 
an increase in xCT expression and ambient glutamate levels which could be activating 
presynaptic mGluRs 2/3 and lowering the relative amount of glutamate released in 
response to stimulation as well as the amount of glutamate accumulation in the 
extracellular space.  Furthermore, with a significant decrease in peak in the cortex we also 
found a significant decrease in the total amount of glutamate accumulation which, again, 
can be explained by a potential increase in xCT expression. Our results demonstrate that 
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upregulating GLT-1 with ceftriaxone in the healthy brain has surprisingly little effect on 
glutamate dynamics in multiple brain regions and over a wide range of neural activity.   
4.2.2 LDN Treatment to Increase GLT-1 Expression 
We also used a more recently-developed compound called LDN that increases 
GLT-1 expression through translational mechanisms (Kong et al., 2014). Kong et al. 
(2014) treated SOD1(G93A) mice and a pilocarpine-induced mouse model of epilepsy 
with LDN. In both cases they found that treatment with LDN diminished neuronal 
degeneration and lowered mortality rate. Furthermore, treatment with LDN in the 
APPSw,Ind mouse model of AD significantly improved cognitive function and reduced 
amyloid beta plaques; these benefits were sustained for one month after treatment 
(Takahashi et al., 2015). We used iGluSnFR to visualize the effects of LDN on glutamate 
dynamics in the cortex, hippocampus, and striatum. Interestingly, while LDN increased 
GLT-1 expression, it had no significant effects on glutamate dynamics in all regions 
examined. The beneficial results of LDN are thought to be via an increase in glutamate 
clearance (Kong et al., 2014). However, Kong et al. (2014) used the biochemical uptake 
assay to demonstrate LDN’s ability to increase glutamate clearance. Furthermore, LDN 
increases GLT-1 translationally by activating protein kinase C (PKC) which activates Y-
box binding-1 (YB-1) protein, which has been implicated in interacting with GLT-1 
mRNAs (Tanaka et al., 2010). PKC has been shown to increase NMDAR gating and 
trafficking (Lan et al., 2001) and plays an important role in memory formation (Wang et 
al., 2006). Furthermore, YB-1 is a multifunctional protein involved in the translational 
regulation of multiple proteins (Evdokimova et al., 2006). Therefore, any beneficial 
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effects of LDN treatment could be due to the positive effects of PKC in the brain and 
subsequent phosphorylation of PKC targets and translational regulation of other proteins 
due to YB-1 activation. Our results show that LDN treatment was unable to increase 
glutamate clearance during a wide range of neural activity.  
4.3 Conclusion 
 Using the biochemical uptake assay, it has been shown that ceftriaxone and LDN 
can increase glutamate uptake due to their beneficial effect of increasing GLT-1 
expression. However, we found no beneficial effect of ceftriaxone in the HD 
hippocampus and also uncovered an age-dependent effect of ceftriaxone on GLT-1 
protein expression. As well, in the healthy brain we found no significant effects of 
ceftriaxone or LDN treatment on glutamate uptake. There are many other factors that 
affect glutamate uptake such as other transporters, diffusion, other protein such as kir 4.1, 
as well as posttranslational modifications that affect the functional ability of proteins. 
Taken together, our results emphasize the importance of testing potential drug 
interventions at a clinically relevant age in animal models and that accelerating glutamate 
clearance is much more complex than just simply increasing GLT-1 expression.    
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Chapter 6 APPENDIX 
 
Figure A1: HFS LTP experiments.  (A), representative traces and group averages of 
fEPSP in relation to time. (B) quantification of the fEPSP/time graph. HET mice and WT 
mice injected with ceftriaxone showed an impairment of percent potentiation, revealing a 
significant genotype and treatment effect, respectively.   
 
